Clinical Trial Update: Haploidentical Natural Killer Cells to Treat Refractory or Relapsed Acute Myelogenous Leukemia (AML) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating haploidentical natural killer cells for refractory or relapsed acute myeloid leukemia has terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Snippet

Sponsor: Masonic Cancer Center, University of Minnesota | Conditions: Leukemia, Myelogenous, Acute | Phase 2 | Status: TERMINATED | Results posted: 2013-06-26